Background:
Recent reports had shown that most of clinically amyopathic dermatomyositis (CADM), which showed poor prognosis, was positive for antiMelanoma differentiation-associated gene 5 (MDA5) antibody (Ab). It had been shown that patients not only with lupus but with dermatomyositis (DM) also showed increased type 1 interferon (IFN) signature. MDA5 acts as a cytosolic RNA sensor, which drives type 1 IFN production. These facts suggested that type 1 IFN might have some roles in anti-MDA5 Ab positive patients. Objectives: We evaluated the association of serum type 1 IFN signature and autoantibodies in patients with inflammatory myositis, in particular anti-MDA5 Ab positive patients and anti-aminoacyl-tRNA synthetases (ARS) Ab positive patients. Methods: Sera from 33 inflammatory myositis patients (13 DM, 10 PM and 10 CADM) were studied for type 1 IFN activity, using a functional reporter cell assay. Briefly WISH cells were incubated with serum containing media for 6 hours. Serum IFN signature scores of the incubated cells were evaluated by the sums of gene expressions of Mx1, IFIT3, IFI44L and IFI44 by real time PCR (Reference). Anti-MDA5 Ab and Anti-ARS Ab were measured by ELISA. We divided these patients into three groups, anti-MDA5 Ab positive group (MDA5 group), anti-ARS Ab positive group (ARS group) and double negative group (DN group). We included double positive patients into MDA5 group. The presence of interstitial lung disease (ILD) and the prognosis were also investigated. Results: MDA5 group had 12 patients (8 CADM and 4 DM), ARS group had 8 patients (4 DM, 1 CADM and 3 PM), and DN group had 13 patients (5 DM, 1 CADM and 7 PM). 9 of MDA5 group, 5 of ARS group, and 1 of DN group were complicated with ILD. Serum IFN signature scores of MDA5 group were significant higher than those of ARS group and DN group (12.43 1.406, 2.407, p=0.0005). The most of ARS group showed low serum IFN signature activities. The overall survivals of ARS group were fairer than MDA5 group, but not significantly. The deceased cases of MDA5 group showed especially high serum IFN signature activities. Conclusions: We characterized two major groups in inflammatory myositis patients. ARS group was characterized by low IFN signature with the susceptibility to DM and ILD. MDA5 group was characterized by high serum IFN signature with the high susceptibility to CADM. Our results suggest that these two entities may have different onset mechanisms, leading to different outcomes. References: [1] [1] . The connection between inadequate nutritional status and systemic sclerosis is still not well established. It is important to identify the symptoms of malnutrition, because it is known as a predictor of poor clinical outcome [2] . Objectives: To assess nutritional status in patients with systemic sclerosis. Methods: The study involved fifty-two patients with SSc (44 women and 8 men, mean age 54,3±11,7 year) who were diagnosed according to ACR/EULAR criteria. The assessment of nutritional status was determined by subjective global assessment (SGA), body mass index (BMI) and level of serum albumin. Appetite was assessed by simplified nutritional appetite questionnaire (SNAQ). In all patients hand grip strength and triceps skinfold were established. The C-reactive protein (CRP), lipid profile, and level of haemoglobin/lymphocytes were measured in serum. Results: Inadequate nutritional status was diagnosed in 14 patients (26,9%) with SSc. According to SGA 11 (21,15%) patients had signs of mild malnutrition, while 41 (78,85%) were well-nourished. Considering BMI, 1 patient (1,92%) was underweight, 24 (46,15%) were eutrophic, 21 (40,38%) overweight and 6 (11,54%) obese. Significantly lower BMI had patients with inadequate nutritional status (23,17±4,47 vs. 25,98±3,34; p=0,009) . Low level of serum albumin was detected in 5 patients (9,6%) with SSc. Level of serum albumin and appetite were significantly decreased in patients with inadequate nutritional status (p=0,009; p=0,003). No statistical differences were noticed in hand grip strength, triceps skinfold, lipid profile, levels of CRP and haemoglobin/lymphocytes. Conclusions: Malnutrition in systemic sclerosis is still underestimated clinical issue. This study provides useful data about nutritional status of patients with systemic sclerosis. Altered level of albumin and decreased appetite may lead to worsening in nutritional status. Assessment of nutritional status in this group of patients should be performed regularly, because it can be potentially modified. References: [1] Background: Systemic sclerosis (SSc) is marked by immune dysregulation, inappropriate fibrosis and a vasculopathy for which there is currently no universally accepted disease modifying regimen. Ambrisentan, a selective type A endothelin receptor antagonist (ERA) has known benefits in the treatment of the vasculopathy related to pulmonary arterial hypertension and has been postulated to have anti-fibrotic effects. The additive effect of an ERA in combination with an anti-fibrotic agent has not previously been studied in SSc. Objectives: To determine the safety and efficacy of ambrisentan in combination with an anti-fibrotic agent in early diffuse cutaneous systemic sclerosis (dcSSc). Methods: Patients already on anti-fibrotic therapy for early dcSSc with onset of skin sclerosis less than 48 months before study entry were placed on ambrisentan 5mg daily for 12 months in an open-label study. Laboratory and clinical parameters to assess safety, as well as severity and progression of SSc were obtained at specified intervals. The primary outcome measure was the modified Rodnan skin score (mRSS), and secondary outcomes were the Medsger severity score, the Short Form Health Survey (SF)-36 questionnaire, pulmonary function tests (PFTs), and 2D echocardiograms (echo). Results: A total of 15 patients were recruited who were on anti-fibrotic therapy upon entry of the study, most commonly mycophenolate (14 patients) and 1 patient on methotrexate. Of the patients entering the study, 10 patients (66.7%) completed 12 months of treatment with the study drug. Using intention-to-treat analysis, the mRSS improved significantly with a mean difference in mRSS of -8 from study entry to study end (p=0.000167). Among study completers (n=10), there was a trend for improvement in all but one category of the SF-36 while only the physical health component was of statistical significance (p=0.025). The median Medsger severity scores remained unchanged except for a change in median skin score. No statistically significant change was observed in PFTs and in mean estimated pulmonary arterial pressure by echo for those patients in whom data was obtained at baseline and at 12 months (n=12 and n=5, respectively). The most common adverse events included peripheral edema and dizziness. Two patients withdrew from the study due to intolerance of the study drug. Serious adverse events (SAE's) occurred in 4 study subjects and included scleroderma renal crisis (n=1), upper gastrointestinal bleeding (n=1) and infections (n=2). None of the SAEs were deemed to be related to the study drug.
Conclusions:
In this prospective open-label study of ambrisentan and anti-fibrotic combination therapy in early dcSSc, we observed significant improvements in the mRSS and patient-perceived physical health status on the SF-36. There was no observed change in peripheral vascular involvement and no consistent trend in PFTs. Combination ambrisentan and anti-fibrotic therapy appears relatively safe in this 12-month study. Larger, controlled trials are needed to further investigate the safety and efficacy of combination therapy.
